看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
5 u* j4 S/ X/ h8 K: W9 F+ O% \* [0 Y& `5 @, s% r) T
, {6 P1 U6 h/ z4 B7 }# K0 X. \Currently available feasibility data for possible combination strategies.
g3 B. k- N { d4 |————————————————————————————————4 C$ s5 H$ u! i( C
Combination Feasibility according to preliminary data $ y. J) }0 k! K- o* m$ o+ a
——————————————————————————————————
) z1 x, U" N s0 MBevacizumab + sorafenib Yes, reduced dose 3 j& B/ R" g7 F5 A: z
Bevacizumab + sunitinib† No 9 [* G; E7 p7 E1 c k
Bevacizumab + temsirolimus Yes : P+ N3 k- F( O
Bevacizumab + everolimus Yes 0 ]+ r0 u$ C+ m2 n6 B0 q G7 I: D
Sorafenib + sunitinib ?
$ _9 h/ K& p: C6 H+ _) F* p, K' pSorafenib + temsirolimus Yes, reduced dose + X4 c/ R6 k7 \- [& ]' ?: @/ ]5 n' d
Sorafenib + everolimus Yes, reduced dose
. t/ J. @2 s, u' Q6 V/ E) G1 ZSunitinib + temsirolimus† No " I, k! s3 i9 O5 @( }, E% T( ^ G
Sunitinib + everolimus ? # t" t& U: [/ `8 d/ n+ k$ }
Temsirolimus + everolimus ?
; d) T% x- N: s) X) L; D————————————————————
^8 i. d. {7 D) g" l: _0 e†Led to US FDA warning.
+ h! {( `( y) H3 I) |1 c?: As yet unattempted combination.' f) g4 _# `) P* K& X4 u
|
显身卡
